BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18474771)

  • 1. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.
    Albert DM; Gangnon RE; Grossniklaus HE; Green WR; Darjatmoko S; Kulkarni AD
    Arch Ophthalmol; 2008 May; 126(5):626-31. PubMed ID: 18474771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
    Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
    Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphometric effects of long-term exposure to latanoprost.
    Cracknell KP; Grierson I; Hogg P
    Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of irises with a latanoprost-induced change in iris color.
    Arranz-Marquez E; Teus MA; Saornil MA; Mendez MC; Gil R
    Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies.
    Cracknell KP; Grierson I; Hogg P; Appleton P; Pfeiffer N
    Exp Eye Res; 2003 Dec; 77(6):721-30. PubMed ID: 14609560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histology and fine structure of the iris and outflow system following latanoprost therapy.
    Grierson I; Pfeiffer N; Cracknell KP; Appleton P
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iris morphology.
    Teus MA; Arranz-Marquez E
    Ophthalmology; 2008 Feb; 115(2):418-9; author reply 419-20. PubMed ID: 18243921
    [No Abstract]   [Full Text] [Related]  

  • 8. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study).
    Pfeiffer N; Grierson I; Goldsmith H; Appleton P; Hochgesand D; Winkgen A
    Arch Ophthalmol; 2003 Jan; 121(1):23-31. PubMed ID: 12523881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
    Wistrand PJ; Stjernschantz J; Olsson K
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
    Chiba T; Kashiwagi K; Kogure S; Abe K; Shibuya T; Furuichi M; Iijima H; Tsukahara S
    J Glaucoma; 2001 Oct; 10(5):406-10. PubMed ID: 11711839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys.
    Prota G; Vincensi MR; Napolitano A; Selen G; Stjernschantz J
    Pigment Cell Res; 2000 Jun; 13(3):147-50. PubMed ID: 10885672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
    Tsai JC; Sivak-Callcott JA; Haik BG; Zhang J; McLean IW
    J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin-induced iridial pigmentation in primates.
    Selén G; Stjernschantz J; Resul B
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S125-8. PubMed ID: 9154288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latanoprost-induced changes in the iris and trabeculum: an electron-microscopic morphological study.
    Yildirim N; Sahin A; Kara S; Baycu C
    Int Ophthalmol; 2010 Feb; 30(1):93-7. PubMed ID: 19139827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latanoprost-induced iris color darkening: a case report with long-term follow-up.
    Camras CB; Neely DG; Weiss EL
    J Glaucoma; 2000 Feb; 9(1):95-8. PubMed ID: 10708238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latanoprost and pigmentation.
    Grierson I; Jonsson M; Cracknell K
    Jpn J Ophthalmol; 2004; 48(6):602-12. PubMed ID: 15592791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation.
    Imesch PD; Wallow IH; Albert DM
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S117-23. PubMed ID: 9154287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism and clinical significance of prostaglandin-induced iris pigmentation.
    Stjernschantz JW; Albert DM; Hu DN; Drago F; Wistrand PJ
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S162-75. PubMed ID: 12204714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study.
    Chiba T; Kashiwagi K; Chiba N; Ishijima K; Furuichi M; Kogure S; Abe K; Tsukahara S
    Br J Ophthalmol; 2003 Aug; 87(8):956-9. PubMed ID: 12881333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro.
    Drago F; Marino A; La Manna C
    Exp Eye Res; 1999 Jan; 68(1):85-90. PubMed ID: 9986745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.